Accumulation of nanocarriers in the ovary: a neglected toxicity risk?
Accumulation of nanocarriers in the ovary: a neglected toxicity risk?
复制标题
DOI：
10.1016/j.jconrel.2012.02.012
复制
发表时间：
2012-05
期刊：
影响因子：
--
通讯作者：
Andreas Schädlich;Stefan Hoffmann;T. Mueller;Henrike Caysa;C. Rose;A. Göpferich;Jun Li;J. Kuntsche;K. Mäder
中科院分区：
文献类型：
--
作者：
Andreas Schädlich;Stefan Hoffmann;T. Mueller;Henrike Caysa;C. Rose;A. Göpferich;Jun Li;J. Kuntsche;K. Mäder
几种纳米载体系统经常用于现代药物治疗。在静脉内（i.v.）局在不同的小鼠物种和Wistar大鼠中进行了研究，在所有动物中发现纳米颗粒、纳米胶囊和纳米乳剂在卵巢的特定位置处的高度局部蓄积。我们通过体内和体外多光谱荧光成像和共聚焦激光扫描显微镜表征了富集。这项研究的结果强调了早期和全面的体内研究在药物研究中的作用。纳米载体在卵巢中的积累也可能是人类的一个重要毒性问题，但研究结果也可能开辟一个靶向卵巢治疗的新领域。
Several nanocarrier systems are frequently used in modern pharmaceutical therapies. Within this study a potential toxicity risk of all nanoscaled drug delivery systems was found. An accumulation of several structurally different nanocarriers but not of soluble polymers was detected in rodent ovaries after intravenous (i.v.) administration. Studies in different mouse species and Wistar rats were conducted and a high local accumulation of nanoparticles, nanocapsules and nanoemulsions in specific locations of the ovaries was found in all animals. We characterised the enrichment by in vivo and ex vivo multispectral fluorescence imaging and confocal laser scanning microscopy. The findings of this study emphasise the role of early and comprehensive in vivo studies in pharmaceutical research. Nanocarrier accumulation in the ovaries may also comprise an important toxicity issue in humans but the results might as well open a new field of targeted ovarian therapies.